Opinion Statement
Atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) tumors share many clinical, etiologic, and histologic features and likely represent components of a tumor spectrum. In dermatologic oncology, differentiating between AFX and PDS is pivotal as tumors with histological features consistent with PDS are more likely to behave in a clinically aggressive manner. Importantly, the term “pleomorphic dermal sarcoma” (PDS) is a more appropriate designation than “undifferentiated pleomorphic sarcoma” (UPS) for describing deeper, more aggressive, histologically high-grade cutaneous tumors that otherwise resemble AFX. Surgery remains the gold standard for treatment. In the setting of AFX, excision with the Mohs micrographic technique appears to offer superior tumor control rates while maintaining greater tissue preservation over wide local excision and should be considered first line. In the setting of PDS, optimal management is less clear given the paucity of available data. However, due to its greater propensity to recur and metastasize, extirpation with complete tumor margin control appears paramount. The roles of imaging and SLNB in management and clinical outcomes of AFX and PDS are unclear given the lack of available data. In reality, these tools are unlikely to be helpful in most cases of AFX. However, in the setting of PDS, emerging literature indicates that these tumors are inherently higher risk, and thus, imaging and SLNB may be helpful in select cases. Additionally, radiation therapy may be of adjuvant benefit for these tumors when clear surgical margins cannot be obtained. While traditional chemotherapy has been largely ineffectual, the recent discovery of key oncogenetic mutations has allowed for the identification of several potential molecular drug targets that may have a therapeutic role with future study. In the unfortunate setting of metastatic disease, a multidisciplinary approach is optimal. Further studies are needed to establish definitive conclusions regarding risk stratification and best management practices.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer. 1973;31:1541–52.
Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer. 1986;57:368–76.
Iorizzo LJ, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011;37:146–57.
•• Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma. Adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 2012;36:1317–26. One of the first papers clearly defining adverse histologic features differentiating PDS from AFX and demonstrating local recurrence and metastatic rates for PDS.
•• Brenn T. Pleomorphic dermal neoplasms: a review. Adv Anat Pathol. 2014;21:108–30. Review of the spectrum of dermal neoplasms.
•• McCalmont TH. AFX: what we now know. J Cutan Pathol. 2011;38:853. Contemporary review defining the current histopathologic characteristics of AFX.
Cooper JZ, Newman SR, Scott GA, Brown MD. Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases. Dermatol Surg. 2005;31:221–5. Discussion 225
Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol. 1992;16:213–28.
McCalmont TH. Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol. 2012;39:8.
Weedon D, Kerr JF. Atypical fibroxanthoma of skin: an electron microscope study. Pathology. 1975;7:173–7.
Barr RJ, Wuerker RB, Graham JH. Ultrastructure of atypical fibroxanthoma. Cancer. 1977;40:736–43.
Aasi SZ, Leffell DJ, Lazova RZ. Atlas of practical Mohs histopathology. New York: Springer; 2013.
Thum C, Husain EA, Mulholland K, Hornick JL, Brenn T. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma. Ann Diagn Pathol. 2013;17(6):502–7. doi:10.1016/j.anndiagpath.2013.08.004.
Diaz-Cascajo C, Weyers W, Borghi S. Pigmented atypical fibroxanthoma: a tumor that may be easily mistaken for malignant melanoma. Am J Dermatopathol. 2003;25:1–5.
Patterson JW, Konerding H, Kramer WM. “Clear cell” atypical fibroxanthoma. J Dermatol Surg Oncol. 1987;13:1109–14.
Wright NA, Thomas CG, Calame A, et al. Granular cell atypical fibroxanthoma: case report and review of the literature. J Cutan Pathol. 2010;37:380–5.
Kim J, McNiff JM. Keloidal atypical fibroxanthoma: a case series. J Cutan Pathol. 2009;36:535–9.
Hollmig ST, Rieger KE, Henderson MT, West RB, Sundram UN. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma. Am J Dermatopathol. 2013 Apr;35(2):176–9. doi:10.1097/DAD.0b013e318265fb9e.
De Feraudy S, Mar N, McCalmont TH. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol. 2008;32:1111–22.
Monteagudo C, Calduch L, Navarro S, et al. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol. 2002;117:126–31.
Hartel PH, Jackson J, Ducatman BS, Zhang P. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol. 2006;33(Suppl 2):24–8.
Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer. 1997;79:2115–24.
•• Hanlon A, Stasko T, Christiansen D, Cyrus N, Galan A. LN, CD, and Ezrin do not distinguish between atypical fibroxanthoma and undifferentiated pleomorphic sarcoma or predict clinical outcome. Dermatol Surg. 2017;43(3):431–6. doi:10.1097/DSS.0000000000001000. Paper evaluating the ability and utility of various immunohistochemical stains in differentiating between AFX and UPS.
Woyke S, Domagala W, Olszewski W, Korabiec M. Pseudosarcoma of the skin. An electron microscopic study and comparison with the fine structure of spindle-cell variant of squamous carcinoma. Cancer. 1974;33:970–80.
Weiss SW, Goldblum JR. Malignant fibrous histiocytoma (pleomorphic undifferentiated sarcoma). In: Enzinger & Weiss’s soft tissue tumors. 5th ed. Mosby: Elsevier; 2008. p. 403–27.
•• Helbig D, Ihle MA, Putz K, Tantcheva-Poor I, Mauch C, Buttner R, et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal scarcomas. Oncotarget. 2016;7(16):21763–74. doi:10.18632/oncotarget.7845. Paper identifying genetic mutations and therapeutic drug targets in AFX and PDS.
•• Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol. 2014;27(4):502–8. doi:10.1038/modpathol.2013.168. First Paper identifying genetic mutations and therapeutic drug targets in AFX and PDS.
•• Ang GC, Roenigk RK, Otley CC, Kim Phillips P, et al. More than 2 decades of treating atypical fibroxanthoma at Mayo Clinic: what have we learned from 91 patients? Dermatol Surg. 2009;35:765–72. Largest case series of its kind demonstrating tumor control between MMS and WLE.
Seavolt M, McCall M. Atypical fibroxanthoma: review of the literature and summary of 13 patients treated with Mohs micrographic surgery. Dermatol Surg. 2006;32:435–41.
Davis JL, Randle HW, Zalla MJ, Roenigk RK, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg. 1997;23:105–10.
Lum DJ, King AR. Peritoneal metastases from an atypical fibroxanthoma. Am J Surg Pathol. 2006;30:1041.
Schmitt AR, Brewer JD, Bordeaux JS, Baum CL. Staging for cutaneous squamous cell carcinoma as a predictor of sentinel lymph node biopsy results: meta-analysis of American Joint Committee on Cancer criteria and a proposed alternative system. JAMA Dermatol. 2014;150:19–24.
Stadler FJ, Scott GA, Brown MD. Malignant fibrous tumors. Semin Cutan Med Surg. 1998;17:141–52.
Brown MD, Swanson NA. Treatment of malignant fibrous histiocytoma and atypical fibrous xanthomas with micrographic surgery. J Dermatol Surg Oncol. 1989;15:1287–92.
Gonzalez-Garcia R, Nam-Cha SH, Munoz-Guerra MF, et al. Atypical fibroxanthoma of the head and neck: report of 5 cases. J Oral Maxillofac Surg. 2007;65:526–31.
Huether MJ, Zitelli JA, Brodland DG. Mohs micrographic surgery for the treatment of spindle cell tumors of the skin. J Am Acad Dermatol. 2001;44:656–9.
•• Tardío JC, Pinedo F, Aramburu JA, Suárez-Massa D, Pampín A, Requena L, et al. Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated. J Cutan Pathol. 2016;43(2):101–12. doi:10.1111/cup.12603. One of the first papers clearly defining adverse histologic features differentiating PDS from AFX and demonstrating local recurrence and metastatic rates for PDS.
Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327–34. doi:10.1200/JCO.2012.48.5326.
Duran J, Morgan FC, Karia PS, Schmults CD. An evaluation of high-stage cutaneous squamous cell carcinoma outcomes by gender. Br J Dermatol. 2016; doi:10.1111/bjd.15208.
• HH MC, Christiansen D, Stasko T, Washington C, Martinez JC, Brown MD, et al. Clinical spectrum of atypical fibroxanthoma and undifferentiated pleomorphic sarcoma in solid organ transplant recipients: a collective experience. Dermatol Surg. 2012;38(2):230–9. doi:10.1111/j.1524-4725.2011.02180.x. Overview of tumoral subtypes seen in immunosuppressed patients.
Hager S, Makowiec F, Henne K, Hopt UT, Wittel UA. Significant benefits in survival by the use of surgery combined with radiotherapy for retroperitoneal soft tissue sarcoma. Radiat Oncol. 2017;12(1):29. doi:10.1186/s13014-017-0769-0.
Beck JT, Ismail A, Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014;40:980–9.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012;30:777–82.
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat med. 2008;14:1351–6.
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther. 2016;9:203–10. doi:10.2147/OTT.S89967.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
The authors have no financial disclosures to report.
Additional information
This article is part of the Topical Collection on Skin Cancer
Rights and permissions
About this article
Cite this article
Soleymani, T., Tyler Hollmig, S. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma. Curr. Treat. Options in Oncol. 18, 50 (2017). https://doi.org/10.1007/s11864-017-0489-6
Published:
DOI: https://doi.org/10.1007/s11864-017-0489-6